Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein. The article explores the role of catalysis…
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read…
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University's NIH Graduate Training…
BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research…
Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery BOSTON, June 18, 2012 - Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for…
CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca